Table 2.
Characteristics of HCV genotype (GT)3a patients who failed DAA treatment and their drug resistance-associated substitutions detected by Sanger sequencing.
| Pt | Fibrosis Stage | Prior IFN Treatment Experience (Response) | DAA | Baseline HCV RNA (LogIU/mL) | Antiviral Regimen (wks) | Response | Known RAS Detected at Failure by Sanger Sequencing |
|
|---|---|---|---|---|---|---|---|---|
| NS5A | NS5B | |||||||
| 42 | 3 | Naïve | First DAA regimen | 7.0 | SOF + DCV (12) |
Relapser | L31F | none |
| Second DAA regimen | 7.0 | SOF + DCV + RBV (24) |
Relapser | L31F | none | |||
| 43 | 4 | Naïve | First DAA regimen | 5.0 | SOF + DCV (24) |
Relapser | P58S Y93H |
S282T |
| Second DAA regimen | 5.8 | SOF + RBV (48) |
Relapser | P58S Y93H |
none | |||
| 44 | 4 | P-R (Null responder) |
First DAA regimen | 5.9 | SOF + RBV (24) |
Relapser | none | none |
| Second DAA regimen | 6.3 | SOF + DCV + RBV (24) |
SVR12 | n.a. | n.a. | |||
| 45 | 4 | P-R (Null responder) |
First DAA regimen | 4.6 | SOF + RBV (24) |
Relapser | none | none |
| Second DAA regimen | 4.1 | SOF + DCV + RBV (24) |
SVR12 | n.a. | n.a. | |||
Pt = patient; DAA = direct antiviral treatment; wks = weeks; RAS = resistance-associated substitutions.